- Home
- LOAN vs DTIL Comparison
LOAN vs DTIL Comparison
Compare LOAN & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOAN | DTIL |
|---|---|---|
| Founded | 1989 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 123.0M |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LOAN | DTIL |
|---|---|---|
| Price | $4.78 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 40.1K | ★ 253.4K |
| Earning Date | 10-24-2025 | 11-03-2025 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $7,138,128.00 | $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | $34.30 |
| P/E Ratio | $10.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.29 | $3.61 |
| 52 Week High | $6.05 | $8.82 |
Technical Indicators
Market Signals| Indicator | LOAN | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 40.77 |
| Support Level | $4.64 | $4.70 |
| Resistance Level | $4.83 | $5.54 |
| Average True Range (ATR) | 0.14 | 0.40 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 74.77 | 28.71 |
Price Performance
Historical ComparisonAbout LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.